Investing.com - Barclays initiated coverage on Mettler-Toledo (NYSE: MTD ) with an overweight rating and a price target of $1,325.00 on Tuesday.

The research firm highlighted Mettler-Toledo’s favorable positioning within Core Tools, noting that 40% of the company’s revenues come from industrial-based applications across multiple end markets including biopharma, food, core industrial, and specialty chemicals manufacturing.

This revenue mix provides Mettler-Toledo with relative insulation from the biopharma R&D and US A&G end markets compared to peers, protecting the company from major funding-related headwinds affecting much of the sector, according to Barclays.

The firm acknowledged that while Mettler-Toledo faces near-term challenges from tariffs and a shipping delay, these issues create only temporary noise in financial results rather than persistent problems, with management effectively communicating the impact to investors.

Barclays cited additional factors supporting its positive outlook, including management’s strong execution history, the company’s superior margin profile and free cash flow generation compared to peers, and products with average selling prices below $10,000 that serve as mission-critical components in customer workflows.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.